Description_x000D_ General description_x000D_ Monoclonal Anti-LRIG3 (mouse IgG1 isotype) is derived from the hybridoma LRG3-3 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a peptide corresponding to a sequence at the N-terminus human LRIG3 conjugated to KLH. Leucine-rich and immunoglobulin-like domain 3 (LRIG3) belongs to the family of LRIG. LRIG3 mRNA is widely expressed, with the highest levels in the stomach, skin and thyroid._x000D_ Immunogen_x000D_ a peptide corresponding to a sequence at the N-terminus human LRIG3, conjugated to KLH. The corresponding sequence is identical in monkey and share high homology with rat and mouse LRIG3._x000D_ Application_x000D_ Monoclonal Anti-LRIG3 antibody produced in mouse has been used in:_x000D_ • immunoblotting_x000D_ • immunofluorescence_x000D_ • flow cytometry (FACS)_x000D_ Physical form_x000D_ Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide._x000D_ Disclaimer_x000D_ Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals._x000D_ Biochem/physiol Actions_x000D_ Leucine-rich and immunoglobulin-like domain 3 (LRIG3) is implicated in tumorigenesis, psoriasis, neural crest development and complex tissue morphogenesis. LRIG3 interacts with the ErbB family of receptors and Netrin 1.